Monday, September 30, 2019

First targeted therapy for cholangiocarcinoma shows clinical benefit in phase III trial

New data have shown for the first time that targeted therapy can improve the outcome of patients diagnosed with advanced cholangiocarcinoma. Cholangiocarcinoma is a subtype of bile duct cancer with aggressive behavior and poor prognosis. Despite the low incidence, most patients die from the disease and therefore new effective therapies are urgently needed.

from Top Health News -- ScienceDaily https://ift.tt/2msnsex

No comments:

Post a Comment

Scientists say most people need more protein than current guidelines suggest

A new review suggests that doing more exercise and eating more protein than current minimum recommendations may help people stay stronger, s...